Total Payments
$1,311
2022 Payments
$421.53
Companies
2
Transactions
12
Medicare Patients
213
Medicare Billing
$30,152
Payment Breakdown by Category
Research$1,290 (98.4%)
Food & Beverage$21.41 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,290 | 11 | 98.4% |
| Food and Beverage | $21.41 | 1 | 1.6% |
Payments by Type
Research
$1,290
11 transactions
General
$21.41
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $1,290 | 11 | $0 (2022) |
| Gilead Sciences, Inc. | $21.41 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $421.53 | 2 | Regeneron Pharmaceuticals, Inc. ($421.53) |
| 2021 | $868.01 | 9 | Regeneron Pharmaceuticals, Inc. ($868.01) |
| 2018 | $21.41 | 1 | Gilead Sciences, Inc. ($21.41) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/01/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $198.57 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 02/01/2022 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $222.96 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 09/28/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $14.66 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 09/28/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $9.58 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 09/23/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $122.35 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 07/12/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $13.63 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 07/12/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $10.31 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 07/09/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $148.31 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 07/09/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $141.14 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 03/31/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $346.26 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 03/31/2021 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $61.77 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | ||||||
| 12/05/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.41 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 | Regeneron Pharmaceuticals, Inc. | $1,290 | 11 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 57 | 112 | $44,287 | $11,248 |
| 2022 | 4 | 54 | 84 | $28,600 | $8,031 |
| 2021 | 3 | 38 | 63 | $16,351 | $4,509 |
| 2020 | 3 | 64 | 95 | $25,694 | $6,364 |
Total Patients
213
Total Services
354
Medicare Billing
$30,152
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 85 | $28,640 | $7,688 | 26.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $15,647 | $3,560 | 22.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 46 | $13,892 | $3,603 | 25.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 14 | $5,432 | $1,941 | 35.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 12 | $6,756 | $1,827 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 12 | $2,520 | $660.26 | 26.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 23 | $6,974 | $1,846 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 15 | 26 | $5,570 | $1,452 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 14 | $3,807 | $1,210 | 31.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 31 | 61 | $13,115 | $3,483 | 26.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 20 | 20 | $8,935 | $2,103 | 23.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 14 | $3,644 | $777.98 | 21.3% |
About Dr. Christopher Hurt, M.D
Dr. Christopher Hurt, M.D is a Infectious Disease healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1033321021.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Hurt, M.D has received a total of $1,311 in payments from pharmaceutical and medical device companies, with $421.53 received in 2022. These payments were reported across 12 transactions from 2 companies. The most common payment nature is "" ($1,290).
As a Medicare-enrolled provider, Hurt has provided services to 213 Medicare beneficiaries, totaling 354 services with total Medicare billing of $30,152. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Chapel Hill, NC
- Active Since 05/04/2007
- Last Updated 06/22/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033321021
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Chapel Hill
David Wohl, M.d, M.D
Infectious Disease — Payments: $941,907
Infectious Disease $941,907
Dr. Joseph Eron, Md, MD
Infectious Disease — Payments: $227,043
Infectious Disease $227,043
Dr. David Van Duin, M.d, M.D
Infectious Disease — Payments: $85,138
Infectious Disease $85,138
Dr. Myron Cohen, Md, MD
Infectious Disease — Payments: $59,254
Infectious Disease $59,254
Dr. David Margolis, Md, MD
Infectious Disease — Payments: $44,821
Infectious Disease $44,821
Dr. Michelle Floris-Moore, Md, MD
Infectious Disease — Payments: $26,360
Infectious Disease $26,360